Wook-Je Cho (L), CEO of Yuhan Corporation, and Anna Jo, CEO of J INTS BIO

Yuhan Cor­po­ra­tion to pay $325M to in-li­cense pre­clin­i­cal HER2 can­di­date

Yuhan Cor­po­ra­tion said Tues­day that it is pay­ing up to $325 mil­lion to fel­low South Ko­re­an biotech J INTS Bio to li­cense an oral non-small cell lung can­cer drug.

The deal is for JIN-A04, a pre­clin­i­cal oral ty­ro­sine ki­nase in­hibitor tar­get­ing NSCLC with HER2 ex­on 20 mu­ta­tions.

J INTS Bio said back in Feb­ru­ary that pre­clin­i­cal da­ta on the mol­e­cule would be pre­sent­ed at the Amer­i­can As­so­ci­a­tion for Can­cer Re­search’s an­nu­al meet­ing in Or­lan­do, say­ing that the mol­e­cule “showed po­tent ef­fi­ca­cy against HER2 Ex­on20 in­ser­tion mu­tant NSCLC cell lines, and in-vi­vo mouse mod­els us­ing HER2 Ex­on20 in­ser­tion mu­tant cell lines sig­nif­i­cant tu­mor re­gres­sion was demon­strat­ed.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.